검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Platinum Doublet |
Overview Company | Merck Sharp & Dohme LLC |
Overview Modality | ANTIBODY |
Overview Target | Autoimmune Disease |
Overview Indication | Autoimmune Disease; Crohn Disease |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeting PI3K/AKT/mTOR pathway |
MoA Biomarker | PD-1/anti-PD-L1 mAb or cisplatin/vinorelbine+anti-PD-1/anti-PD-L1 mAb had high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Comparable Effectiveness of Weight-Based and Fixed-Dose Pembrolizumab in Non-Small Cell Lung Cancer: Insights From a National Real-World Cohort.. Pembrolizumab, a PD-1 immune checkpoint inhibitor (ICI), is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). Although fixed-dose pembrolizumab (200 mg once every 3 weeks) is widely used based on pharmacokinetic modeling, i… |
Clinical Primary efficacy | ORR 100% |
Clinical ORR | 100% |
Clinical Result source | ClinicalTrials.gov NCT04989218 |
Clinical Data Tier / Score | A · 60 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Platinum Doublet |
Overview Company | Merck Sharp & Dohme LLC |
Overview Modality | ANTIBODY |
Overview Target | Autoimmune Disease |
Overview Indication | Autoimmune Disease; Crohn Disease |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeting PI3K/AKT/mTOR pathway |
MoA Biomarker | PD-1/anti-PD-L1 mAb or cisplatin/vinorelbine+anti-PD-1/anti-PD-L1 mAb had high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Comparable Effectiveness of Weight-Based and Fixed-Dose Pembrolizumab in Non-Small Cell Lung Cancer: Insights From a National Real-World Cohort.. Pembrolizumab, a PD-1 immune checkpoint inhibitor (ICI), is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). Although fixed-dose pembrolizumab (200 mg once every 3 weeks) is widely used based on pharmacokinetic modeling, i… |
Clinical Primary efficacy | ORR 100% |
Clinical ORR | 100% |
Clinical Result source | ClinicalTrials.gov NCT04989218 |
Clinical Data Tier / Score | A · 60 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교